New COVID-19 vaccine trial includes children as young as 3

NCT ID NCT04869592

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new recombinant COVID-19 vaccine (made using CHO cells) in healthy people aged 3 and older. The trial involved 3,100 participants across two phases to check safety, side effects, and immune response. Participants received either a low or high dose of the vaccine or a placebo, with three shots given over 60 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Recombinant SARS-CoV-2 vaccine (CHO cell)

What this could lead to

If successful, this could provide a safe and effective COVID-19 vaccine option for people as young as 3 years old.

What could go wrong

This is an early-phase trial focused on safety and immune response, not yet proven to prevent COVID-19. Results may not apply to newer virus variants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ning ling Center for Disease Control and Prevention

    Shangqiu, Henan, China